Market revenue in 2023 | USD 153.1 million |
Market revenue in 2030 | USD 342.4 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.92% in 2023. Horizon Databook has segmented the Brazil immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil has an established healthcare infrastructure in the LATAM region, with world-class research centers engaged in studies on neurology and other fields. Clinical research is one of the major pillars and is leading certain advances.
The Brazil immunoassay for neurological biomarkers market is dominated majorly by foreign players, such as F. Hoffmann-La Roche Ltd., Merck, and Johnson & Johnson Services, Inc. Availability of abundant resources, including cheap labor costs and a large target population make Brazil the major choice of international players for their businesses.
In April 2018, Siemens Healthcare GmbH developed the Enterprise Project with Hermes Pardini Group of Minas Gerais, Brazil to transform care delivery in the field of in vitro diagnostics. This initiative was anticipated to drive the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Brazil immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account